Skip to main content
Message Font: Serif | Sans-Serif
No. of Recommendations: 0

Tiger Lilly or Wilting Daisy?
By Stephen D. Simpson, CFA
July 21, 2005

This could well be one of those quarters that Eli Lilly (NYSE: LLY) management will be happy to forget. Sales growth was pretty feeble and the company decided to write a big check to make drug litigation go away.

On the sales side, total revenue grew 3% as reported, but 2% of that growth came from currency benefits. Although the contribution of new drugs as a percentage of sales climbed again on a sequential basis to 17%, a decline in Zyprexa and diabetes products put a damper on the growth...
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.